What do systematic reviews say?

Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical

Anti‐leukaemic therapy plus alemtuzumab showed no clear difference in serious adverse events compared with anti‐leukaemic therapy alone (anti‐leukaemic therapy identical (moderate certainty).

• Alemtuzumab for patients with chronic lymphocytic leukaemia 2012 · Cochrane Headline outcomes only
  RR 1.34 [0.95, 1.89]
  2 studies · 350 participants
  Moderate

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher serious adverse events (longest available compared with standard therapy (moderate certainty).

• Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple… 2024 · Cochrane Headline outcomes only
  Risk Ratio 1.18 [1.02, 1.37]
  3 studies · 1644 participants
  Moderate

Cytarabine plus high‐dose methotrexate vs high‐dose methotrexate alone

The review found no eligible studies for this question.

• Role of chemotherapy additional to high‐dose methotrexate for primary central nervous system lymphoma (PCNSL) 2012 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma 2021 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 281 participants
  Very low